SCHEMBL2296847

SCHEMBL2296847

COCC(NC(=O)c1cc(-c2ccc(Nc3nc4ccc(F)cc4s3)cc2)no1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 10/20 0.53
DGAT1 O75907 2/20 0.53
MAPT P10636 5/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44
TNF P01375 1/20 0.44
NR2F2 P24468 1/20 0.44
HTT P42858 1/20 0.44
MCL1 Q07820 1/20 0.44
KLF5 Q13887 1/20 0.44
NOD1 Q9Y239 1/20 0.44
ALDH1A1 P00352 2/20 0.43
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2296831 1.00 CSGALNACT1 (0.53) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2297992 0.94 CSGALNACT1 (0.49) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2298000 0.94 CSGALNACT1 (0.49) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2298179 0.92 CSGALNACT1 (0.50) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2298195 0.92 CSGALNACT1 (0.50) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2299698 0.92 CSGALNACT1 (0.46) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2299710 0.92 CSGALNACT1 (0.46) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2293683 0.91 CSGALNACT1 (0.49) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL3238703 0.91 CSGALNACT1 (0.49) CSGALNACT1DGAT1MAPTNPC1RAB9A
SCHEMBL2293690 0.91 CSGALNACT1 (0.49) CSGALNACT1DGAT1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US claimed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT CSGALNACT1 455/4885DGAT1 1/4885MAPT 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.